These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22087614)

  • 1. A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.
    McDermott CL; Hsieh AA; Sweet ES; Tippens KM; McCune JS
    J Altern Complement Med; 2011 Nov; 17(11):1043-9. PubMed ID: 22087614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
    Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
    J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality of information on the internet relating to top-selling dietary supplements in the Czech Republic.
    Baudischova L; Straznicka J; Pokladnikova J; Jahodar L
    Int J Clin Pharm; 2018 Feb; 40(1):183-189. PubMed ID: 29177614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the quality of internet information for breast cancer.
    Nghiem AZ; Mahmoud Y; Som R
    Breast; 2016 Feb; 25():34-7. PubMed ID: 26547835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
    Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An instrument to evaluate pharmacists' patient counseling on herbal and dietary supplements.
    Lin HW; Pickard AS; Mahady GB; Karabatsos G; Crawford SY; Popovich NG
    Am J Pharm Educ; 2010 Dec; 74(10):192. PubMed ID: 21436933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
    Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
    J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation Breast Cancer Information on The Internet in Arabic.
    Alnaim L
    J Cancer Educ; 2019 Aug; 34(4):810-818. PubMed ID: 29923058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of internet websites marketing herbal weight-loss supplements to consumers.
    Jordan MA; Haywood T
    J Altern Complement Med; 2007 Nov; 13(9):1035-43. PubMed ID: 18047451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to pharmacists adopting professional responsibilities that support the appropriate and safe use of dietary supplements in the United States: Perspectives of key stakeholders.
    Ung COL; Harnett JE; Hu H; Desselle SP
    Am J Health Syst Pharm; 2019 Jun; 76(13):980-990. PubMed ID: 31361883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    Miller WR; Bartlett J; Brodie AM; Brueggemeier RW; di Salle E; Lønning PE; Llombart A; Maass N; Maudelonde T; Sasano H; Goss PE
    Oncologist; 2008 Aug; 13(8):829-37. PubMed ID: 18695261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary supplement survey of pharmacists: personal and professional practices.
    Howard N; Tsourounis C; Kapusnik-Uner J
    J Altern Complement Med; 2001 Dec; 7(6):667-80. PubMed ID: 11822615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What do evaluation instruments tell us about the quality of complementary medicine information on the internet?
    Breckons M; Jones R; Morris J; Richardson J
    J Med Internet Res; 2008 Jan; 10(1):e3. PubMed ID: 18244894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary and herbal supplements for weight loss: assessing the quality of patient information online.
    Ng JY; Ahmed S; Zhang CJ
    Nutr J; 2021 Jul; 20(1):72. PubMed ID: 34315485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
    Hertz DL; Henry NL; Rae JM
    Pharmacogenomics; 2017 Apr; 18(5):481-499. PubMed ID: 28346074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.